Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, safinamide (Xadago®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with idiopathic Parkinson's disease as add-on therapy to a stable dose of levodopa (L-dopa) alone or in combination with other Parkinson's disease medicinal products in mid- to late-stage fluctuating patients. |
||
|
||
Medicine details |
||
| Medicine name | safinamide (Xadago®) | |
| Formulation | 50 mg film-coated tablet, 100 mg film-coated tablet | |
| Reference number | 2493 | |
| Indication | For the treatment of adult patients with idiopathic Parkinson's disease as add-on therapy to a stable dose of levodopa (L-dopa) alone or in combination with other Parkinson's disease medicinal products in mid- to late-stage fluctuating patients. |
|
| Company | Zambon SpA | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 26/06/2015 | |
| Date of issue | 30/06/2015 | |